These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24930087)

  • 21. Serelaxin and acute heart failure.
    Tietjens J; Teerlink JR
    Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 23. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
    Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
    Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Alternatives to conventional diuretic therapy in heart failure].
    Morales-Rull JL; Trullàs JC; Formiga F
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():42-8. PubMed ID: 24930083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Organ damage and cardiorenal syndrome in acute heart failure].
    Casado Cerrada J; Pérez Calvo JI
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():26-31. PubMed ID: 24930080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relaxin: a novel agent for the treatment of acute heart failure.
    Wilson SS; Ayaz SI; Levy PD
    Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
    Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
    Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vasoactive and inotropic drugs in acute heart failure].
    Ruiz-Laiglesia FJ; Camafort-Babkowski M
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():49-54. PubMed ID: 24930084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic therapy for acute heart failure.
    Tang WH
    Cardiol Clin; 2007 Nov; 25(4):539-51; vi. PubMed ID: 18063158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of emerging pharmacologic agents for acute heart failure syndromes.
    De Luca L; Mebazaa A; Filippatos G; Parissis JT; Böhm M; Voors AA; Nieminen M; Zannad F; Rhodes A; El-Banayosy A; Dickstein K; Gheorghiade M
    Eur J Heart Fail; 2008 Feb; 10(2):201-13. PubMed ID: 18279775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serelaxin in clinical development: past, present and future.
    Unemori E
    Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms.
    Núñez J; Miñana G; Santas E; Bertomeu-González V
    Rev Esp Cardiol (Engl Ed); 2015 May; 68(5):426-35. PubMed ID: 25758162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
    Varr BC; Maurer MS
    Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 36. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond.
    Cotter G; Milo O; Davison BA
    Curr Heart Fail Rep; 2014 Mar; 11(1):19-30. PubMed ID: 24363020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure?
    Dschietzig TB
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):343-55. PubMed ID: 24934696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.